HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis

HTLV-1 复制/重新激活诱导的 DNA 损伤:机制和发病机制

基本信息

  • 批准号:
    10572907
  • 负责人:
  • 金额:
    $ 22.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-11-14 至 2024-10-31
  • 项目状态:
    已结题

项目摘要

The human T-cell leukemia virus type 1 (HTLV-1) is a complex human delta retrovirus that infects 10-20 million people worldwide. Approximately 3-5% of infected individuals develop an intractable T cell malignancy known as adult T cell leukemia/lymphoma (ATL) decades later. How HTLV-1 infection progresses to ATL is not fully understood. Two viral regulatory proteins, Tax and HBZ, encoded by the sense and antisense viral mRNA transcripts, respectively, are crucial for causing ATL. Tax, the viral trans-activator/oncoprotein, is a robust activator of viral replication and IKK/NF-κB signaling, and a potent clastogen that induces DNA double-strand breaks (DSBs). It is thought to be the cause for the extensive genomic instability of ATL, which, on average, contains 59.5 structural variations in its genome. We recently discovered that NF-κB hyperactivation by Tax results in the co-transcriptional accumulation of a nucleic acid structure known as an R-loop. And R-loop excision by Xeroderma pigmentosum F (XPF) and XPG, two endonucleases of the transcription-coupled nucleotide excision repair (TC-NER) pathway, leads to DNA DSBs. This finding provides a mechanistic explanation for the genomic instability of ATL and the senescence-inducing activities of Tax. Indeed, NF-κB blockade prevents Tax- induced R-loop accumulation, DNA damage, and senescence. And the silencing of XPF and XPG mitigates Tax senescence, while deficiency in either or both frequently occurs in ATL cells of all types. Importantly, NF-κB is constitutively active in ATL, and ATL cells are resistant to Tax-senescence, suggesting that they have evolved adaptive changes to benefit from the survival and proliferation advantages conferred by Tax and NF-κB. Considering our discoveries outlined above and recent evidence showing that Tax is expressed intermittently in intense bursts in ATL cell lines and HTLV-1-infected T lymphocytes cultured ex vivo, we posit that most de novo HTLV-1 infections result in active viral replication, during which potent NF-κB activation by Tax drives the accumulation of R-loops that promote DNA DSBs, leading to senescence. In a fraction of infected T cells, HTLV- 1 proviruses likely integrate into transcriptionally quiescent chromosomal regions, establishing latent viral infection. During latency, HBZ, expressed from a distinct promoter in the 3’ LTR, dampens Tax activities to inhibit viral replication and, at the same time, stimulates the clonal expansion of the latently infected cells. We further posit that Tax, expressed intermittently during viral reactivation, targets R-loops and DNA DSBs to specific NF- kB-regulated genes, causing their inactivation and facilitating ATL development. Finally, we hypothesize that during ATL evolution, gain-of-function mutations and copy number variants of interferon regulatory factor 4 (IRF4) gene are selected to enable cellular adaptation to the DNA damage and senescence response induced by Tax and NF-κB. We will test these hypotheses in two specific aims: Aim 1 To determine how Tax/NF-κB - induced R-loops impact host cell genome and cell fate. Aim 2 To elucidate how ATL cells accommodate chronic NF-κB activation.
人类T细胞白血病病毒1型(HTLV-1)是一种COMPREX人类三角病毒,感染10-20个感染个体的10-20个棘手的T细胞恶性肿瘤,称为成人T细胞白血病/淋巴瘤(ATL)HTLV-1感染如何ATL的进展不是完全的。有效的Clastogen DNA链链破裂(DSB)。核酸结构的tran脚本积累,称为R-L环和R-loop Concision。 ATL基因组不稳定性的机理解释和税收的衰老活性,NF-κB封锁征税诱导的R环,DNA损害,DNA损害以及XPF和XPG的税收减轻税收自由地发生在所有类型的ATL细胞中上面概述了上面的概述,最近的证据表明税收是ATL LINS和HTLV-1感染的tlymphocytes培养的体内的强烈爆发,这些体内大多数从头htlv-1感染都会导致主动病毒复制,在此期间,税收驱动力的有效的NF-κB激活了税收驱动力的积累。促进DSB的R环,导致衰老,在感染的T细胞中,HTLV-1速率在转录静止的染色体区域中,建立了潜在的病毒感染。我们感染了感染的细胞。选择IRF4基因以使细胞适应DNA损伤和室内室内的ERMINE税/NF-κB诱导的R环如何影响宿主细胞基因组和细胞命运,以阐明ATL如何适应慢性NF-κB活化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHOU-ZEN GIAM其他文献

CHOU-ZEN GIAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHOU-ZEN GIAM', 18)}}的其他基金

Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8052727
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8607791
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8396677
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    7866744
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8448784
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8265753
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8607461
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8791965
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Cell Cycle Regulation and Adult T Cell Leukemia
细胞周期调节和成人 T 细胞白血病
  • 批准号:
    8214695
  • 财政年份:
    2010
  • 资助金额:
    $ 22.78万
  • 项目类别:
Carl Zeiss LSM 510 Confocal Inverted Microscope System
Carl Zeiss LSM 510 共焦倒置显微镜系统
  • 批准号:
    7389697
  • 财政年份:
    2008
  • 资助金额:
    $ 22.78万
  • 项目类别:

相似国自然基金

Tenascin-X对急性肾损伤血管内皮细胞的保护作用及机制研究
  • 批准号:
    82300764
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
活性脂质Arlm-1介导的自噬流阻滞在儿童T细胞急性淋巴细胞白血病化疗耐药逆转中的作用机制研究
  • 批准号:
    82300182
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
  • 批准号:
    82370165
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
  • 批准号:
    82300697
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
KIF5B调控隧道纳米管介导的线粒体转运对FLT3-ITD阳性急性髓系白血病的作用机制
  • 批准号:
    82370175
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Functional, structural, and computational consequences of NMDA receptor ablation at medial prefrontal cortex synapses
内侧前额皮质突触 NMDA 受体消融的功能、结构和计算后果
  • 批准号:
    10677047
  • 财政年份:
    2023
  • 资助金额:
    $ 22.78万
  • 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
  • 批准号:
    10651082
  • 财政年份:
    2023
  • 资助金额:
    $ 22.78万
  • 项目类别:
LRP1 as a novel regulator of CXCR4 in adult neural stem cells and post-stroke response
LRP1 作为成体神经干细胞和中风后反应中 CXCR4 的新型调节剂
  • 批准号:
    10701231
  • 财政年份:
    2023
  • 资助金额:
    $ 22.78万
  • 项目类别:
Mechanisms of Cardiac Injury Resolution by CX3CR1+ Macrophages
CX3CR1巨噬细胞解决心脏损伤的机制
  • 批准号:
    10719459
  • 财政年份:
    2023
  • 资助金额:
    $ 22.78万
  • 项目类别:
Investigating cerebrovascular dysfunction and cerebral atrophy in severe traumatic brain injury
严重颅脑损伤中脑血管功能障碍和脑萎缩的调查
  • 批准号:
    10742569
  • 财政年份:
    2023
  • 资助金额:
    $ 22.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了